Hunan Jiudian Pharmaceutical Co Ltd banner

Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705

Watchlist Manager
Hunan Jiudian Pharmaceutical Co Ltd Logo
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Watchlist
Price: 13.65 CNY -1.09% Market Closed
Market Cap: ¥6.8B

Hunan Jiudian Pharmaceutical Co Ltd
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Hunan Jiudian Pharmaceutical Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Hunan Jiudian Pharmaceutical Co Ltd
SZSE:300705
Total Current Assets
¥1.6B
CAGR 3-Years
13%
CAGR 5-Years
29%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Assets
¥35.6B
CAGR 3-Years
11%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Assets
¥51.5B
CAGR 3-Years
19%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Assets
¥34B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
7%
Zhejiang Nhu Co Ltd
SZSE:002001
Total Current Assets
¥19.4B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Assets
¥6.3B
CAGR 3-Years
146%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Hunan Jiudian Pharmaceutical Co Ltd
Glance View

Market Cap
6.8B CNY
Industry
Pharmaceuticals

Hunan Jiudian Pharmaceutical Co Ltd, nestled amidst the vibrant commercial landscape of China, exemplifies the dynamic evolution of the pharmaceutical industry within the region. Founded on the principles of innovation and resilience, the company has carved a niche by focusing on the development, production, and sale of a variety of active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates through an intricate web of research and development that is deeply aligned with the latest advancements in medical science. Central to its operations is a robust R&D facility that not only ensures high-standard quality control but also keeps the pipeline brimming with potential new products. This forward-thinking approach is critical, as it continually feeds the market with pharmaceuticals that cater to both chronic and acute health conditions, ranging from anti-infectives to cardiovascular drugs. The company capitalizes on a vertically integrated business model, which substantially aids in controlling cost and quality across all stages of production. By managing a seamless supply chain that extends from raw material procurement to drug distribution, Hunan Jiudian Pharmaceutical ensures both operational efficiency and market competitiveness. Revenue streams largely flow from the sale of its proprietary products in domestic and international markets, supported by a comprehensive marketing strategy and a broad distribution network. This pragmatic blend of science, strategy, and salesmanship allows the company not only to generate profits but also to contribute significantly to the global pharmaceutical framework, marking its presence as a formidable player in this ever-changing industry.

Intrinsic Value
11.83 CNY
Overvaluation 13%
Intrinsic Value
Price ¥13.65

See Also

What is Hunan Jiudian Pharmaceutical Co Ltd's Total Current Assets?
Total Current Assets
1.6B CNY

Based on the financial report for Sep 30, 2025, Hunan Jiudian Pharmaceutical Co Ltd's Total Current Assets amounts to 1.6B CNY.

What is Hunan Jiudian Pharmaceutical Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
29%

Over the last year, the Total Current Assets growth was -1%. The average annual Total Current Assets growth rates for Hunan Jiudian Pharmaceutical Co Ltd have been 13% over the past three years , 29% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett